Stratasys (SSYS) Q4 2025 earnings review
Cost Discipline Saves the Year, But Tariffs Cap 2026 Upside
Stratasys capped off a difficult 2025 with a 6.9% YoY revenue decline in Q4 to $140.0M, pressured by a prolonged slump in capital equipment spending. However, aggressive cost controls implemented throughout the year proved effective: full-year Operating Cash Flow nearly doubled to $15.1M, and Adjusted EBITDA grew 9.6% to $28.5M despite the topline contraction. The company's strategic pivot to production-scale manufacturing continues to gain traction, now accounting for 37.5% of total revenue. Yet, the outlook for 2026 is a mixed bag. While management expects revenue growth to resume, profitability is projected to stall due to a massive $17 million headwind from tariffs and foreign exchange rates.
🐂 Bull Case
The transition from prototyping to high-value manufacturing applications is paying off. Manufacturing use cases grew to 37.5% of total revenue in 2025, up from 25% in 2020. Deep integration with aerospace giants (Airbus, Boeing) and automotive leaders (Rivian, Subaru) validates the technology at scale.
Stratasys exited 2025 with $244.5M in cash and zero debt. This financial resilience allows them to easily weather the current capex drought and positions them to opportunistically acquire distressed assets in a consolidating industry.
🐻 Bear Case
Guidance implies revenue will grow in FY26, but Adjusted EBITDA is forecasted to be flat or down. A projected $17M hit from tariffs and FX is severely capping bottom-line recovery.
Hardware sales remain the weak link. Q4 Systems revenue plummeted 19.1% YoY to $37.8M. Customers are still delaying major capital expenditures, keeping the core growth engine idled.
⚖️ Verdict: ⚪
Neutral. Management deserves credit for squeezing $28.5M of EBITDA out of a shrinking topline through sheer operational discipline. However, until the macro environment clears and Stratasys can prove it has the pricing power to offset tariff costs, significant margin expansion remains out of reach.
Key Themes
Accelerating Penetration in Production Manufacturing
The multi-year pivot toward production-scale 3D printing is accelerating. Manufacturing applications constituted 37.5% of FY25 revenue (up from 36% in FY24). This is driven by deep integrations in Aerospace & Defense and Automotive. Key wins include Boeing purchasing F3300 printers for production tooling, Rivian deploying 28 systems at 90% utilization, and Airbus producing over 25,000 flight-ready parts in 2025. This transition is critical as manufacturing machines consume up to 10x more high-margin material than prototyping units.
Gross Margins Compressed by External Shocks
Non-GAAP Gross Margin decelerated significantly in Q4, dropping to 46.3% from 49.6% a year ago. Management cited a severe impact from tariffs and foreign exchange rates. More alarmingly, these pressures are structural going into 2026: the company is guiding for a $7M gross margin hit from logistics, materials, tariffs, and FX next year, limiting the ability to expand margins even as volumes recover.
OpEx Discipline Creates a Profitability Floor
A major success story for 2025 was the structural reset of the company's cost base. Despite FY25 revenues dropping by $21.4M vs FY24, Non-GAAP Operating Expenses were slashed from $342.5M to $299.8M. This stable operational rigor pushed FY25 Non-GAAP net income up to $12.7M (from $4.2M) and nearly doubled operating cash flow. Management has proven they can protect the downside.
Systems Hardware Still in a Deep Freeze
The capital expenditure freeze among industrial customers remains a persistent headwind. While Consumables revenue grew 2.4% YoY in Q4, Systems revenue decelerated violently, plunging 19.1% YoY to $37.8M. Until customers unlock budgets for large capital outlays, Stratasys is heavily reliant on its installed base to drive incremental growth.
Medical Advisory Board to Drive Healthcare AM
Building on the success of its Industrial Customer Advisory Board, Stratasys launched a new Medical Advisory Board. Featuring senior executives from giants like Medtronic and Edwards Lifesciences, this signals a formalized, aggressive push to standardize and scale additive manufacturing specifically for regulatory-heavy clinical, orthopedic, and cardiac applications.
Other KPIs
Accelerating. Nearly doubled from $7.8M in 2024, proving that the company's aggressive restructuring and cost controls are translating into real cash generation despite the challenging revenue environment.
Stable. The balance sheet remains rock-solid with zero debt. This gives the company immense optionality to navigate the extended macro downturn and execute on inorganic growth/M&A strategies.
Reversing to positive. Grew 2.4% YoY. This is a bright spot indicating that despite weak hardware sales, the existing installed base of printers is being actively utilized by customers, driving high-margin recurring revenue.
Guidance
Reversing. After a 3.7% decline in FY25 to $551.1M, management expects a return to top-line growth (implied midpoint growth of ~3.4%). The growth is expected to improve sequentially throughout the year, suggesting a back-half weighted recovery in capital spending.
Decelerating. Despite forecasting higher revenues, the Adjusted EBITDA midpoint ($27.5M) is slightly below FY25's actual result ($28.5M). This stagnation is directly tied to the expected $17M combined adverse impact from tariffs and foreign exchange rates.
Stable. The outlook is largely in line with FY25's actual Non-GAAP gross margin of 46.9%. However, it explicitly bakes in roughly $7M of adverse impacts from logistics, tariffs, and FX relative to 2025.
Key Questions
Pricing Power vs Tariffs
Guidance explicitly cites a $17M combined headwind from tariffs and FX for 2026. What specific pricing actions or supply chain shifts are being deployed to mitigate this, and why isn't there more confidence in passing these costs to end-users?
Systems Hardware Recovery
Systems revenue dropped 19% in Q4. While full-year 2026 revenue guidance implies growth, does this rely on a broad macro recovery in hardware capex, or is it strictly tied to specific, already-contracted production programs rolling out?
M&A Strategy and Asset Integration
With $244.5M in cash, the company is well-capitalized for acquisitions. Can you provide an update on the integration of IP/assets acquired earlier in the year (like Nexa3D/Forward AM), and what specific technology gaps are prioritized for future M&A?